Non-small Cell Lung Cancer Stage III Clinical Trial
Official title:
ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study
It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain high relative dose intensity of anticancer treatments. Food supplement ONCOXIN (ONCX) contains amino acids, vitamins, minerals and biologically active substances of natural origin with high immunostimulatory and antioxidant activity. Present study is a real world experience study intended to evaluate the efficacy of ONCX in cancer patients.
The study was conducted at 9 centers across the Russia and Kazakhstan. Patients were
allocated in 2:1 comparison groups for the ONCX and control groups, respectively. A total of
133 patients were enrolled in the study; 84 in the ONCX group and 49 as controls.
ONCX contains microelements, vitamins, amino acids and certain naturally occurring,
biologically active substances.
It is expected that additional support with certain micronutrients may improve prognosis,
decrease the frequency of side effects and complications and maintain the Quality of life in
cancer patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05557552 -
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer
|
N/A | |
| Active, not recruiting |
NCT04765709 -
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT06449313 -
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06031597 -
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
|
Phase 3 | |
| Recruiting |
NCT04728724 -
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05451173 -
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT06015815 -
The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
|
||
| Completed |
NCT03728556 -
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04586465 -
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT05548504 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT02434081 -
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT02946216 -
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
|
N/A | |
| Recruiting |
NCT05398094 -
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
|
Phase 2 | |
| Completed |
NCT02418234 -
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
|
N/A | |
| Recruiting |
NCT05338619 -
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT05414630 -
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT04941365 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
N/A | |
| Not yet recruiting |
NCT06463665 -
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)
|
Phase 2 | |
| Active, not recruiting |
NCT04699721 -
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC
|
Phase 1 | |
| Recruiting |
NCT04878952 -
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
|
N/A |